|Bid||2.6200 x 800|
|Ask||2.6700 x 1800|
|Day's Range||2.6100 - 2.8698|
|52 Week Range||2.4100 - 9.9800|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.29|
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that results from a pivotal trial were published online in the Annals of Internal Medicine® journal. A Diagnostic Accuracy Study," demonstrated decisive evidence for the first direct-from-blood, non-culture test cleared by the U.S. Food and Drug Administration (FDA) for the diagnosis of bloodstream infections by multiple bacteria. The T2Bacteria® Panel received FDA clearance in May 2018 and is the first and only FDA-cleared test to identify sepsis-causing bacteria directly from whole blood without the wait for blood culture, which currently takes 1 to 5 or more days and is the current standard of care for diagnosing bloodstream infections (BSIs).
The inducement awards consist of options to purchase 10,500 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $2.78, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on May 8, 2019.
LEXINGTON, Mass., May 08, 2019 -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in.
T2 Biosystems (TTOO) delivered earnings and revenue surprises of -13.33% and 31.83%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Lexington, Massachusetts-based company said it had a loss of 34 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Exceeds Q1 Guidance with Delivery of $1.8 Million in Revenue and 11 New Instrument Contracts Confirms 2019 Guidance of a Doubling of Revenue and Securing 70 – 80 T2Dx.
Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.
Better-than-expected performance at C&V and Cardiac & Neuromodulation product lines and higher revenues might aid Integer Holdings (ITGR) in Q1. But decline in non-medical sales might be a dampener.
T2 Biosystems (TTOO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LEXINGTON, Mass., April 18, 2019 -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs.
The latest earnings update T2 Biosystems, Inc. (NASDAQ:TTOO) released in December 2018 suggested company earnings became less negative compared to the previous year's level - great news for investors...
LEXINGTON, Mass., April 03, 2019 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical.
T2 Biosystems, Inc.'s (NASDAQ:TTOO): T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. The US$119m market-cap company announced a latest lossRead More...
Secured 14 New Instrument Contracts in the Fourth Quarter and 39 total New Instrument Contracts in 2018 that are expected to drive growth in Recurring Test Revenue Confirms.
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
This is a nice win for this razor and razor-blade concern and helped drive a 15% rally in T2 Biosystems on Thursday. This trial combined the use of TG Therapeutics' compounds TG-1101 and TGR-1202 and Imbruvica to treat chronic lymphocytic leukemia or small lymphocytic lymphoma. After the bell Thursday, TG Therapeutics took advantage of the rally in the stock to initiate a raise of capital.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 27) Abbott Laboratories (NYSE: ABT ) argenx SE – ADR (NASDAQ: ...
The FDA has granted T2 Biosystems, Inc. (TTOO) “Breakthrough Device” designation for the T2Resistance Panel, a diagnostic panel that can detect 13 resistance genes from both gram-positive and gram-negative pathogens from a single patient blood sample, without the wait for blood culture. The 13 genes identified on the panel include the most clinically important, as they are largely resistant to antimicrobial drugs that for certain patients, are crucial in the treatment of bacterial infections, including carbapenems, vancomycin, penicillin and more.
NEW YORK, Feb. 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
T2 Biosystems, Inc. (TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to present at the 8th Annual SVB Leerink Global Healthcare Conference. Mr. McDonough and John Sprague, chief financial officer, will be available for one-on-one meetings during the conference. The presentation will be webcast live and available for replay, and may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com.
LEXINGTON, Mass., Feb. 20, 2019 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical.
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, was recognized today by Fast Company among the top 10 of the world’s most innovative companies in the biotech category. The award comes just over 6 months after the launch of the T2Bacteria® Panel, the first and only FDA-cleared test to identify sepsis-causing pathogens directly from whole blood in 3 to 5 hours without the wait for blood culture, which can take 1 to 6 days or more. It is one of several panels that are approved or in development that are run on the Company’s T2Dx® Instrument, which is powered by miniaturized magnetic resonance (T2MR®) technology.